Pharmaceutical - Pharmaceutical, UK

Filter

Current filters:

PharmaceuticalUK

Popular Filters

1 to 25 of 198 results

UK NICE wants more info on type 2 diabetes drug Jardiance

UK NICE wants more info on type 2 diabetes drug Jardiance

28-08-2014

In a new draft guidance issued today, the UK drugs watchdog the National Institute for Health and Care…

Boehringer IngelheimDiabetesEli LillyJardiancePharmaceuticalPricingRegulationUK

EXPERT VIEW: Pay-for-delay - GSK’s wait is almost over…

EXPERT VIEW: Pay-for-delay - GSK’s wait is almost over…

22-08-2014

If GlaxoSmithKline thought that the demise of the Office of Fair Trading (OFT) on April 1 would bring…

Activist UK LimitedGenericsGlaxoSmithKlineLicensingPatentsPharmaceuticalSeroxatUK

Insulin offers new hope for the treatment of acute pancreatitis

22-08-2014

Acute pancreatitis involves the pancreas digesting itself resulting in severe abdominal pain, vomiting…

DiabetesInflammatory diseasesPancreas disordersPharmaceuticalResearchUK

Pfizer could try to acquire Actavis as back-up to a further bid for AstraZeneca

Pfizer could try to acquire Actavis as back-up to a further bid for AstraZeneca

22-08-2014

While speculation continues as to whether Pfizer will resume its attempts to buy AstraZeneca, Pfizer…

ActavisAstraZenecaBusiness FinanceIrelandMergers & AcquisitionsPfizerPharmaceuticalSwedenUKUnited StatesUSA

Clinigen adds to oncology portfolio with AstraZeneca’s Ethyol

Clinigen adds to oncology portfolio with AstraZeneca’s Ethyol

20-08-2014

UK-based Clinigen Group has acquired the global rights to the oncology support therapy Ethyol (amifostine)…

ClinigenClinigen GroupEthyolLicensingOncologyPharmaceuticalTreatment for head and neck cancerUK

US DoJ closes investigation into AstraZeneca’s PLATO trial for Brilinta

US DoJ closes investigation into AstraZeneca’s PLATO trial for Brilinta

19-08-2014

Anglo-Swedish drug major AstraZeneca has received confirmation from the US Department of Justice that…

AstraZenecaBrilintaBrilintaCardio-vascularLegalPharmaceuticalUKUSA

NICE says benefit of prostate cancer drug Zytiga does not justify price

NICE says benefit of prostate cancer drug Zytiga does not justify price

15-08-2014

The UK’s National Institute for Health and Care Excellence (NICE) has not recommended Zytiga (abiraterone)…

AbirateroneAndrew DillonJanssenOncologyPharmaceuticalRegulationUKZytiga

Kadcyla’s rejection confirms that NICE must change the way it considers cancer treatment, says analyst

Kadcyla’s rejection confirms that NICE must change the way it considers cancer treatment, says analyst

13-08-2014

“The National Institute for Health and Care Excellence’s recent rejection of Kadcyla, Roche’s latest…

KadcylaOncologyPharmaceuticalPricingRegulationRocheUK

Scottish Medicines Consortium approves Roche's subcutaneous RoActemra for NHS use

Scottish Medicines Consortium approves Roche's subcutaneous RoActemra for NHS use

11-08-2014

The Scottish Medicines Consortium has approved the prescribing on the National Health Service of Roche’s…

Anti-Arthritics/RheumaticsImmunologyImmunosuppressantsNHSPharmaceuticalRegulationRoActemraRocheTocilizumabUK

Clinigen backs white paper calling for recognition of early access schemes

Clinigen backs white paper calling for recognition of early access schemes

08-08-2014

UK-based Clinigen Group has published a new International Society for Pharmaceutical Engineering (ISPE)…

Clinigen GroupHealthcarePharmaceuticalRegulationUKUnited States

NICE disappointed by Roche’s decision on Kadcyla pricing

NICE disappointed by Roche’s decision on Kadcyla pricing

08-08-2014

UK health care cost watchdog the National Institute for Health and Care Excellence (NICE) said this morning…

Breast cancerCancerKadcylaNational Health ServiceOncologyPharmaceuticalPricingRegulationRocheUK

NICE comes back with different views on Tarceva and Iressa for NSCLC

NICE comes back with different views on Tarceva and Iressa for NSCLC

07-08-2014

UK health costs watchdog the National Institute for Health and Care Excellence (NICE) is consulting again…

AstraZenecaIressaOncologyPharmaceuticalPricingRegulationRocheTarcevaUK

New blood cancer injection given green light by UK regulators

New blood cancer injection given green light by UK regulators

05-08-2014

Patients in the UK with one of the most common forms of blood cancer can now benefit from a new injection.…

Andrew DaviesLymphomaMabTheraNHSOncologyPharmaceuticalRegulationRituximabRocheUK

Vernalis achieves research milestones in Servier oncology collaborations

Vernalis achieves research milestones in Servier oncology collaborations

04-08-2014

UK biopharmaceutical company Vernalis and Servier, France’s largest independent drugmaker, say that…

FinanceFinancialFranceIan GarlandOncologyPharmaceuticalResearchServierUKVernalis

Altacor growth to accelerate after acquisition by Esperante

Altacor growth to accelerate after acquisition by Esperante

01-08-2014

The private, Netherlands-based life science investment company Esperante says it has completed the acquisition…

AltacorDean SlagelEsperanteIn vitro diagnosticsMergers & AcquisitionsNetherlandsNicOxNYSE EuronextOphthalmicsPharmaceuticalProducerUK

GSK and Genmab announce positive interim results for ofatumumab Phase III

GSK and Genmab announce positive interim results for ofatumumab Phase III

01-08-2014

UK Pharma major GlaxoSmithKline and Danish biotechnology company Genmab have said that an interim analysis…

Chronic lymphocytic leukemiaDenmarkGenmabGSKOfatumumabOfatumumab InjectionOncologyPharmaceuticalRafael AmadoResearchUK

AstraZeneca 2nd-qtr earnings leap, beating expectations

AstraZeneca 2nd-qtr earnings leap, beating expectations

31-07-2014

Anglo-Swedish pharma major AstraZeneca, which earlier this year defended itself against an unsolicited…

AstraZenecaBusiness FinanceFinancialPharmaceuticalUK

NICE consulting again on Celgene's Revlimid for multiple myeloma

NICE consulting again on Celgene's Revlimid for multiple myeloma

31-07-2014

The UK clinical guidance body, the National Institute for Health and Care Excellence (NICE), is again…

Celgene Corp.ImmunosuppressantslenalidomideOncologyPharmaceuticalRegulationRevlimidUK

AstraZeneca and Kyowa Hakko Kirin sign immunotherapy research deal

AstraZeneca and Kyowa Hakko Kirin sign immunotherapy research deal

30-07-2014

Anglo-Swedish pharma major AstraZeneca today announced that it has entered into a clinical study collaboration…

AstraZenecaBriggs MorrisonImmunologyJapanKyowa Hakko KirinOncologyPharmaceuticalResearchUK

1 to 25 of 198 results

Back to top